Podcasts about preimplantation

Take a sneak peek at this month's Fertility and Sterility! Articles discussed this month are:   02:59 Preimplantation genetic testing for aneuploidy is associated with reduced live birth rates in fresh but not frozen donor oocyte in vitro fertilization cycles: an analysis of 18,562 donor cycles reported to Society for Assisted Reproductive Technology Clinic Outcome Reporting System 19:37 Sperm concentration remains stable among fertile American men: a systematic review and meta-analysis 26:02 Preovulation body mass index and pregnancy after first frozen embryo transfer in patients with polycystic ovary syndrome and insulin resistance 36:54 A retrospective comparison of the impact of industry payments on assisted reproductive technology practice and outcomes 44:55 Preimplantation genetic testing for aneuploidy in unexplained recurrent pregnancy loss: a systematic review and meta-analysis 61:03 Initiation and outcomes of women pursuing planned fertility preservation 65:49 First successful ovarian cortex allotransplant to a Turner syndrome patient requiring immunosuppression: broad implications   View Fertility and Sterility October 2025, Volume 123, Issue 1: https://www.fertstert.org/issue/S0015-0282(24)X0014-X View Fertility and Sterility at https://www.fertstert.org/

58 Applications for Preimplantation Genetic Diagnosis Accepted in Japan in 2023

PGT allows important insight into the well-being of embryos created during IVF. Join Dr. Carrie Bedient from The Fertility Center of Las Vegas, Dr. Abby Eblen from Nashville Fertility Center and Dr. Susan Hudson from Texas Fertility Center, as they discuss what important information you can learn about your embryos through pre-implantation genetic testing. They discuss what PGT is, what types of PGT are available, and address new testing on the horizon.  Learn how PGT can bring you another step closer to aa healthy baby. Have questions about infertility?  Visit FertilityDocsUncensored.com to ask our docs. Selected questions will be answered anonymously in future episodes.Today's episode is brought to you by Needed and Path Fertility 

What's the scoop about PGT-A? Join Dr. Carrie Bedient from The Fertility Center of Las Vegas, Dr. Abby Eblen from Nashville Fertility Center and Dr. Susan Hudson from Texas Fertility Center for straight talk about preimplantation genetic testing that screens embryos created through IVF for chromosomal abnormalities. While it's not a crystal ball, testing does detect certain genetic defects. Our docs discuss carrier screening, too. Have questions about infertility? Visit FertilityDocsUncensored.com to ask our docs. Selected questions will be answered anonymously in future episodes.Today's episode is brought to you by Cicero Diagnostics and Fertility Pharmacy of America

Dr. Alan Martinez discusses pre-implantation genetic testing for polygenic disorders called PGT-P.

Dr. Eric Forman is the medical and lab director at Columbia University Fertility Center. Dr. Forman is one of the most respected doctors in country and his research sets the standard for other doctors. At Columbia University Fertility Center he oversees the medical practice as well as IVF embryology and andrology labs, while also actively seeing patients with infertility and those seeking to preserve their fertility as well. He has published more than 40 articles in peer-reviewed journals on a wide range of topics in assisted reproductive technology (ART). You can contact Dr. Eric Forman here: Instagram: @ericformanmd Connect with Lisa Pineda here: Website www.lisapinedayoga.com TEDx Talks: How Yoga Helped Me to Let Go & How Meditation Can Unlock Your True Potential --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/lisa-pineda/support

As a teen, Jessica learned firsthand of the degenerative disease that afflicted many of her family members as she helped care for her grandmother.  Years later, when she was ready to start her own family, she knew wanted spare the next generation if she could.  Learn how she used preimplantation genetic testing for (PGT-M) to prevent transmission to her children. Find the #StartwithSART Fertility Experts series wherever you get your podcasts. Looking for advice on building a family? Ask the experts and #StartwithSART. For more information about the Society for Assisted Reproductive Technology, visit our website at https://www.sart.org Have a topic you'd like to hear? Tell Us!

Episode 411. Topic:  Preimplantation genetic diagnosis. Theme:  Embryos. How can IVF allow for embryo screening?  How does this screening work? Why is  preimplantation genetic testing performed and what are the outcomes? Why can it be controversial?Twitter: @3minutelesson  Email: 3minutelesson@gmail.com  Instagram: 3minutelesson  Facebook: 3minutelesson  New episode every Monday, Wednesday, and Friday! Find us everywhere podcasts are found.  

For a long time, couples who carried the thalassaemia gene - either in one or both parents - had few options when it came to starting a family, and these options often came with difficult decisions. Preimplantation genetic testing, along with in-vitro fertilisation, has given couples the chance to reduce the risk of having a baby with thalassaemia. We explore how preimplantation genetic testing is done, and address the most common concerns regarding this procedure, with Dr Eeson Sinthamoney, Director & Fertility Specialist; and Michelle Lim, Senior Pre-Implantation Genetic Testing Specialist, from Sunfert International Fertility Centre.This show is brought to you by EP Plus Group Sdn Bhd. For more information visit https://www.sunfert.com

After discovering the cause of your baby's death is a rare genetic disorder, what can you do to avoid history repeating itself? Episode seven of the Making It To Motherhood series hears Maya talk about the world of genetics and the journey her and husband Rich underwent to ensure that their future children would not be born with NKH - the rare genetic and sadly terminal condition that caused their son Leo to die at just 10 days old. Zinnia and Maya also chat about some of the everyday ups and downs that surround baby loss and the challenges of having another.

As a parent, you would do whatever you could to ensure that your child has a good life. But what if you knew that your unborn child would have a condition that would severely impact their quality of life? What if you could, at the earliest possible stage, choose against this?Featured:Dr Peter Illingworth, Medical Director, IVF AustraliaProfessor Isabel Karpin, School of Law, University of Technology SydneySteph Agnew, disability and IVF advocateProducer/Presenter: Toby Hemmings

Dr. Shannon M. Clark discusses IVF with preimplantation genetic screening with REI Specialist, Dr. Jenny Hirshfeld-Cytron @drjennyhirshfeld. --- Support this podcast: https://anchor.fm/adoctordeliverspodcast/support

This episode focuses on preimplantation genetic testing (PGT). Dr. Cengiz Cinnioglu walks us through the process of PGT or embryo screening. Today we are able to biopsy embryos at the blastocyst stage and send the biopsy for genetic analysis prior to embryo transfer. The ability to test an embryo before embryo transfer is one of the greatest accomplishments in IVF.

We spoke with Noor Siddiqui about how Orchid is using polygenic risk scores for common diseases for preimplantation screening. The Bioinformatics CRO is a fully distributed contract research company that serves the computational biology needs of biotechnology companies, with a focus on genomics. https://www.bioinformaticscro.com/

Dr. Rachel Schwartz Gerber returns to Healthful Woman, this time to discuss preimplantation genetic testing. This type of testing is fairly new, and is used to check an embryo’s genetics before IVF to ensure it is viable and healthy.

Dr. Juan Alvarez shares his insight on everything you need to know regarding preimplantation genetic testing.

"One of the biggest challenges that PGT (preimplantation genetic testing) has presented to the field of IVF is this phenomenon of mosaic results - these results that neither clearly normal nor clearly abnormal but somewhere in between." - Emily Mounts, MS, CGC Mosaicism is very challenging topic and there are many unknowns that clinicians deal with regularly. ASRM Today speaks with Emily Mounts who is the Director of Genomic Services and a genetic counselor with ORM Fertility in Oregon, about the recent ASRM Practice Committee Opinion on "Clinical management of mosaic results from preimplantation genetic testing for aneuploidy (PGT-A) of blastocysts". Emily Mounts is a board-certified genetic counselor at ORM Fertility. She has been practicing in prenatal and reproductive genetics for over 20 years and is the Immediate Past Chair of the ASRM Genetic Counseling Professional Group. She is one of the primary authors of the forthcoming ASRM Committee Opinion publication, Clinical management of mosaic results from preimplantation genetic testing for aneuploidy (PGT-A) of blastocysts. This Practice Committee Opinion will be available on August 5, 2020. To view this and all ASRM's Practice Committee documents, visit ASRM.org If you'd like to know more about the types of practice documents and the methodology of their creation, visit this page on ASRM.org

Live Online Journal Club discussing three cutting-edge scientific papers on preimplantation genetic testing (PGT) and its impact in reproductive medicine. Guest speakers: Dr. Richard Scott, Dr. Juan Antonio García-Velasco, Dr. Julia Kim, Dr. Dagan Wells, Dr. Marta Shahbazi. Moderators: Dr. Emre Seli, Dr. Andres Reig.

"One of the biggest challenges that PGT (preimplantation genetic testing) has presented to the field of IVF is this phenomenon of mosaic results - these results that neither clearly normal nor clearly abnormal but somewhere in between." - Emily Mounts, MS, CGC Mosaicism is very challenging topic and there are many unknowns that clinicians deal with regularly. ASRM Today speaks with Emily Mounts who is the Director of Genomic Services and a genetic counselor with ORM Fertility in Oregon, about the recent ASRM Practice Committee Opinion on "Clinical management of mosaic results from preimplantation genetic testing for aneuploidy (PGT-A) of blastocysts". Emily Mounts is a board-certified genetic counselor at ORM Fertility. She has been practicing in prenatal and reproductive genetics for over 20 years and is the Immediate Past Chair of the ASRM Genetic Counseling Professional Group. She is one of the primary authors of the forthcoming ASRM Committee Opinion publication, Clinical management of mosaic results from preimplantation genetic testing for aneuploidy (PGT-A) of blastocysts. This Practice Committee Opinion will be available on August 5, 2020. To view this and all ASRM's Practice Committee documents, visit ASRM.org If you'd like to know more about the types of practice documents and the methodology of their creation, visit this page on ASRM.org

In BONUS Episode 237 of Beat Infertility, Dr. Mike Large, senior director of research at CooperGenomics, about preimplantation genetic testing and mosaicism in 2020. If you need additional support, consider joining Hope University or our Infertility Warrior Tribe. For details on both, please visit https://beatinfertility.co/hopeu.  

In BONUS Episode 237 of Beat Infertility, Dr. Mike Large, senior director of research at CooperGenomics, about preimplantation genetic testing and mosaicism in 2020. Infertility coach Heather Huhman helps warriors like you make scientifically-based, well-informed decisions about your next steps. To schedule your free 30-minute call, go to https://beatinfertility.co/hope.

Preimplantation genetic testing has opened up a world of helping families have successful pregnancies. But when does the testing and selection of embryos go too far? In this episode of Inside Reproductive Health, Griffin talks to Dr. Jamie Metzl, author of Hacking Darwin: Genetic Engineering and the Future of Humanity. They discuss the implications of advanced technologies such as the future of embryo screening and gene-editing. More importantly, Dr. Metzl discusses the significance of understanding the coming technologies and how those in the fertility field can help prepare their patients and the rest of the world for these changes.

This week Molly ponders PGT-A, Preimplantation Genetic Testing for Aneuploidy (the latest version of PGS). PGT-A helps doctors identify abnormal embryos before transferring them into the uterus to help avoid failed cycles, miscarriages, or having a child with severe health problems. Sounds great, right? But not all doctors are on board with it. What’s the deal?! Why?! Molly digs deep to get to the bottom of her own feelings about PGT-A with the help of doctors, listeners, strangers from the internet and friends of the podcast.Want to know what's happening with Molly's womb in real time while supporting this independent podcast? Subscribe to patreon.com/spermcastGot questions? Call or text 323-741-1818 or email Molly at spermcast@gmail.comCheck out the SpermCast Website!Follow SpermCast here: Instagram // Twitter // Facebook // Follow Amanda here: Instagram See acast.com/privacy for privacy and opt-out information.

In this podcast, Dr. Mark Damario, a Reproductive Endocrinologist and Infertility Specialist with the Center for Reproductive Medicine, presented at Ridgeview Medical Center's Live Friday CME Series on May 24, 2019. At this event, Dr. Damario provided insights to the emerging roles of assisted reproductive technologies. Enjoy the podcast! Objectives:    Upon completion of this podcast, participants should be able to: Describe the role of assisted reproductive technologies for infertile and non-infertile conditions. Differentiate the various forms of assisted reproductive technologies. Identify changes and new developments in assisted reproductive technologies. CME credit is only offered to Ridgeview Providers for this podcast activity. Complete and submit the online evaluation form, after viewing the activity.  Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within 2 weeks.  You may contact the accredited provider with questions regarding this program at  rmccredentialing@ridgeviewmedical.org. Click on the following link for your CME credit: CME Evaluation: "Update in Assisted Reproductive Technologies" (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition.”   FACULTY DISCLOSURE ANNOUNCEMENT  It is our intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker’s outside interest may reflect a possible bias, either the exposition or the conclusions presented. Planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. SHOW NOTES:  INTRODUCTION: Dr. Damario is the medical director of the Center for Reproductive Medicine in St. Paul, MN; and is a practicing reproductive medicine specialist who earned his medical degree at the Medical College of Virginia, and completed his OB/GYN residency there as well. He then went on to complete fellowships in reproductive surgery at Emory University and reproductive endocrinology at Cornell. We were delighted to have him join us on May 24, 2019, to provide his insights and updates on assisted reproductive technology. CHAPTER 1: ART (assisted reproductive technology) was initially done in rabbit models, and then the first successful IVF birth in humans in 1978. Use of oocyte donation in 1983, a surrogate mother in 1986. Pre-implantation genetic dx in an embryo in 1989, and a single sperm injected in an egg in 1992. These were major breakthroughs. Where is ART these days? There are over 500 clinics in the U.S. that contribute for the most part to the national database on stats for ART. Ultimately, there are over 65,000 live births, and the percentage is now about 1.9% of total babies born now in the U.S.   Forbes.com in 2012, estimated 900,000 approximately conceived persons in the U.S. derived from IVF. That's about 305 people at Times Square bumping into each other on any given day. In 2017, the trend of multiple pregnancies in IVF and ART has come down. This issue has been contentious in the field of ART. Triplets in particular happen less often. Less than 1% from 7% in the mid-1990s. Twins have decreased in rate as well. Oocyte cryopreservation has continued to increase, as it is much more efficient now for donor and fertility preservation. More elective single embryo transfers as well. Indications for IVF include: Tubal factors such as occluded or absent tubes are indications, Male factors, such as severe oligospermia is also an indication for IVF. Advanced endometriosis and failed induction of ovulation, diminished ovarian reserve, unexplained infertility and a variety of specific conditions, such as the need for pre-implantation genetic diagnosis are also indications. Dr. Damario's program treats women age less than 45 with their own eggs and less than 50 with donor eggs. Smoking is a contraindication. BMI is also an issue for patients. Assessment of the woman will include antimullerian hormone (which has key roles in folliculogenesis), basal antra follicle count by U/S (an ovarian follicle in the latter stage of formation) and less often day 3 FSH and estradiol. Sonohysterography or saline hysterography, semenalysis, and sperm penetration testing, cervical canal evaluation, testing for Hep B and C, HIV and Syphilis are also performed ahead of time. How does the treatment phase of IVF work? Pituitary inhibition needs to happen in order to suppress the LH surge before oocyte retrieval. OCPs are given ahead of time to suppress other ovarian cysts, and to help start some of the later fertility medications. Pituitary suppression with Lupron or antagonists, such as Ganorelix. The gonadotropins are given after withdrawal bleeding from discontinuation of the pill and for about 8 to 12 days. Ultrasounds for follicles and estradiol accounts are performed. HCG is then given if all looks well with the above steps. It is similar to LH and then oocyte retrieval is scheduled 36 hours later. This is a precise action so as to not have egg immaturity or have ovulation occur. Embryo transfer then happens on the 5th day, most commonly. Usually then a pregnancy test happens on the 9th day. egg retrieval occurs transvaginally with ultrasound guidance. This is a day surgery procedure, and is generally tolerated well. Dr. Damario shows a short video of the procedure at this time. The embryologist takes the follicular fluid to ID eggs. They are graded for maturity, and they simultaneously prepare sperm. Eggs are incubated, then are exposed to sperm. They are observed the following day, embryos cleave and then on days 3 to 5, the embryo is transferred. A mature egg is actually the largest cell in the human body, and is surrounded by a clump of cells called a corona. Micro-droplet of sperm onto the egg and intracytoplasmic injection of a single sperm injected into the egg can also be done, especially if sperm quality is lower. The embryo is then cultured and grown, with cell division occurring daily and exponentially. A morula, which is many cells, is followed by a blastocyst forming, which is an expansion with an inner cell mass and fluid space. At this stage, the embryo is felt to be doing well. If they're not doing well, the embryo won't be chosen for transfer. Egg fertilization occurs at a rate of about 75%. The embryo is transferred into the uterus with transabdominal U/S guidance as it is placed into the uterus. Little to no anesthesia is required for this. CHAPTER 2: Outcomes are impacted by age to a fair degree, obviously higher (success) in younger women. The older the patient the less likely it will take effect. Cryogenically preserved embryos are doing well in transfer, in fact slightly better in some cases than traditional transfer. Risks of IVF include: multiple pregnancies, ovarian hyperstimulation syndrome, bleeding and infection, which are rare. Adverse pregnancies such as ectopic and miscarriage can occur. There is a possibility of subtle increase in congenital anomalies. Third party reproduction options include: oocyte donation from someone, sperm donation, embryos donated and gestational surrogate. This involves gestational carrier of the couple's own embryo. Oocyte donation is performed win carious ovarian failure conditions in general. Anonymous donors are screened very well, and hopefully in a hormonally synchronized recipient. They will be maintained on hormones through the first trimester in most cases. Oocyte donation has a very good success; especially with the improvement of cryopreservation. In older women, for instance up to age 45, there is good success with this procedure. Beyond 45 yo, there is lack of sufficient data to support doing this. Gestational carrier is indicated when there is no uterus, uterine complications, substantial risk to patient due to other conditions, same sex male couples for instance. Fertility preservation is performed in instances of cancer treatment. These include oocyte, sperm and embryo cryopreservation. These are experimental, but are coming down the pipeline in the future. Fertility preservation is not a guarantee that it will work but the odds do go up proportionate to the number of eggs frozen; although this does decline the older you are. Preimplantation genetic screening: random chromosome abnormalities, or embryonic aneuploidy is screened for more often now. Age of the woman is an impact, although problems can be derived from sperm too, but there is no age impact in men. Embryos can be screened for such things as SC disease and CF. Now embryos are biopsied at day 5, and the trophectoderm (outer layer) is sampled for this. The embryo is the frozen after biopsy. These samples are sent to national labs for this. Usually, affected embryos will not be transferred. Next generation sequencing testing modalities are used commonly now. A significant proportion of anuploid embryos are found now, actually. It appears, for instance, that women who are of older gestational age, are to benefits most from genetic testing. Gestational carrier cases are also good reason for genetic testing, since the surrogate will be taking on a significant risk in carrying the child. CHAPTER 3: Evolving ART.  Major advances have been made in many areas. Cryopreservation, genetic testing and counseling, etc. We're not quite there yet with oocyte in-vitro maturation. Essentially embryonic stem cell therapy is still being done, but more adult stem cells are being used. Mitochondrial transfer therapy for mitochondrial diseases are being done in the U.K.  Germ line gene editing, for instance, to have HIV protection, has come up at a recent conference. This is in the very early stages of development though. Question from the audience: Pre-implantation genetic diagnosis - how many things can be screened for? PGS is still for a limited list of conditions, mostly the disease conditions are monogenic. Sex chromosome reports are also obtained. But, this is not done only for sex selection, especially in fertile couples. When appropriate, this can be chosen, however.  There is a slight chance of error, but certainty is very high. Other questions included freezing of eggs. Not only in dire circumstances such as cancer, but also for women who may want to wait to have children for any variety of reasons. Vitrification is the method used for this now which is essentially "flash freezing" and has been perfected over the past 7-8 years. Also, Dr. Damario mentions that studies show that visualized hydrosalpinx on U/S is associated with poorer IVF outcomes. Salpingectomy can improve chances with this. Cost is also addressed, and of course when insurance doesn't cover the cost of ART, there is a significant expense to the patient. Screening tests are commonly covered by insurance. Finally, Dr. Damario comments on a question regarding egg transfer. Transferring eggs to someone else is not a simple task and is governed by the FDA, much like transplant surgery.  

Reproductive medicine has advanced dramatically and often presents couples with complex choices that can only be made on an individual basis. Preimplantation genetic screening or testing (PGS) is a powerful technology employed before implantation to help identify genetic defects within embryos. However, the process is extremely sophisticated and complex, therefore requiring a tremendous amount of experience and skill on the part of the reproductive endocrinologist. The procedure also comes with potential ethical concerns regarding the existing limits of the test.In this episode, Serena Chen, M.D., director for the division of reproductive medicine in the Department of Obstetrics and Gynecology at Saint Barnabas Medical Center and a clinical associate professor at Rutgers, UMDNJ Medical School, joins host Mark P. Trolice, M.D., to share her insights on the potential benefits and limitations of preimplantation genetic testing.Tune in to discoverThe history of preimplantation genetic screening (PGS) and its evolution until todayThe limits of PGS and the controversy surrounding an embryo’s ability to self-correctThe potential risks inherent in the PGS procedureWhat mosaic embryos are and why they are dividing IVF expertsWho might benefit the most from preimplantation genetic testingAbout Serena H. Chen, M.D.Serena H. Chen, M.D. graduated from Brown University in Providence Rhode Island. She attended Duke University School of Medicine in Durham, North Carolina, and then trained in Gynecology and Obstetrics and Reproductive Endocrinology and Infertility at the Johns Hopkins Hospital in Baltimore, Maryland. After completion of her fellowship, she served as an Assistant Professor at the Johns Hopkins University School of Medicine, as well as an Attending at the Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. Dr. Chen serves as Director for the Division of Reproductive Medicine in the Department of Obstetrics and Gynecology at Saint Barnabas Medical Center, and the Institute for Reproductive Medicine and Science at Saint Barnabas, and is a Clinical Associate Professor at Rutgers, UMDNJ Medical School and the St George’s University School of Medicine.Dr. Chen has published multiple papers and has been the recipient of scientific grants, including the prestigious Stetler Research Grant and the Johns Hopkins Institutional Research Grant. She also has received an award for achievement in laparoscopic surgery from the Society of Laparoendoscopic Surgeons. Dr. Chen has served as a reviewer for scientific journals such as Fertility and Sterility, the European Journal of Obstetrics & Gynecology and Reproductive Biology, and Reproductive BioMedicine Online. She works actively with patient advocacy groups such as INCIID, RESOLVE and the American Fertility Association, serving on the Physician Advisory Boards, writing patient articles, hosting online chats, serving as a Web Angel on the AFA and IRMS message boards and speaking at many patient education seminars. In 2005, the AFA recognized these efforts with a Family Building Award.About Mark P. Trolice, M.D.Mark P. Trolice, M.D., FACOG, FACS, FACE is Director of Fertility CARE: The IVF Center in Winter Park, Florida and Associate Professor of Obstetrics & Gynecology (OB/GYN) at the University of Central Florida College of Medicine in Orlando responsible for the medical education of OB/GYN residents and medical students as well as Medical Endocrinology fellows. He is past President of the Florida Society of Reproductive Endocrinology & Infertility (REI) and past Division Director of REI at Winnie Palmer Hospital, part of Orlando Health.He is double Board-certified in REI and OB/GYN, maintains annual recertification

February 2019 See acast.com/privacy for privacy and opt-out information.

In this month's Taboo-ty Podcast episode, we interview Serena Talcott Baughman, MS, CGC, Genetic Counselor. The discussion is about preimplantation genetic testing, also called PGT, which can be used to identify embryos at risk of having a specific genetic or chromosomal condition (for example, Lynch syndrome or FAP). Learn more about PGT on this podcast as we dive into the science, process, controversy, and basic information of this technology.

Preimplantation genetic screening in recent years has shown improved outcomes for couples with infertility who are going through IVF. Mosaicism or embryos that can be predicted to be a mix of normal and abnormal cells have changed the landscape of screening and what questions might arise as a result of that screening.Dr. William Ziegler discusses Mosaicism and how it might affect fertility options and treatment for couples trying to conceive.

Filmed at the CPM's event 'Personalised Medicine in Practice: Advances in Reproductive Science' on 7th March 2017, Dagan Wells gives his talk 'The evolution of preimplantation genetic diagnosis: karyomapping and beyond'. Dagan Wells has been actively involved in preimplantation genetic diagnosis (PGD) and the study of human gametes and embryos for almost 25 years. He spent several years at University College London, where he accomplished the first comprehensive chromosome analysis of cells from human embryos in 1998. The following year Dagan moved to the United States and joined Reprogenetics, the world’s largest provider of PGD services, initiating their highly successful single gene PGD program. Dagan later joined the faculty of Yale University Medical School, where he set-up a research laboratory, before returning to the UK in 2007. He is now an Associate Professor at the University of Oxford, based at the Nuffield Department of Obstetrics and Gynaecology. After arriving in Oxford, Dagan established Reprogenetics-UK, a laboratory offering state-of-the-art diagnostic services to IVF clinics, which has grown to become the largest provider of PGD services in the UK. Dagan’s work has led to the publication of over 150 peer-review publications and in the last decade has been shortlisted for seventeen major conference prizes (ASRM and ESHRE), winning nine of them. Dagan is a Fellow of the Royal College of Pathologists and the Royal Society of Biology and currently serves on the Editorial Boards of several international journals.

When Kimberly & her husband, Jacob, couldn't conceive, tests revealed that Kimberly had polycystic ovarian syndrome (PCOS) and Jacob had a zero sperm count. But that wasn't the end of their story—or their diagnoses. "It was like the world stopped." Kimberly shares it all here. -- You might remember Kimberly from Episode 21: Pregnancy After Infertility or Loss (PAIL). You can access that episode by clicking here. -- For more about Sarah's Laughter, please visit our website at sarahs-laughter.com. Our podcast-only site is podcast.sarahs-laughter.com. You can follow us on social media linked here: Sarah's Laughter on Facebook & Instagram, and @sarahs_laughter & @jasonforbus on Twitter. Sarah's Laughter also holds the Baby Steps Fun Run, where we give away a $10,000 grant for expenses related to either adoption or fertility treatment. We also partner with local SART-listed fertility clinics to give away IVFs at the event. Check babystepsfunrun.com for details and schedule.  *** Sarah's Laughter is a 501(c)(3) nonprofit public charity. If you'd like to help support what we do, including this podcast, please visit sarahs-laughter.com/give. Thank you. --  Want to share your infertility story on this podcast? Email us at podcast@sarahs-laughter.com  

We hear more than ever about the secrets hidden in our genes, from our risk of diseases to traits such as intelligence or even sporting ability. But can we really test for them? And just because we can, does that mean we should? Plus, an extremely popular - and extremely distracting - gene of the month. This is the Naked Genetics podcast for October 2016 with me, Dr Kat Arney, brought to you in association with The Genetics Society, online at genetics.org.uk. Like this podcast? Please help us by supporting the Naked Scientists

Preimplantation genetic diagnosis (PGD) allows for the detection of life-altering genetic abnormalities prior to embryo transfer during IVF. The procedure can also help patients suffering from certain fertility challenges as well.The PGD procedure is an evaluation of chromosomes, thread-like structures found in all human cells except red blood cells.The PGD process starts after the embryo is fertilized and allowed to grow, when an embryo biopsy is performed. This procedure involves removing either a polar body, which is half of the maternal DNA, or a blastomere, which is a cell from the embryo that contains its DNA.Alan Martinez, MD, is here to help you better understand Preimplantation genetic testing to identify genetic defects in embryos created through in vitro fertilization (IVF) before pregnancy.

Host Dawn Davenport, Executive Director of Creating a Family, the national infertility & adoption education and support nonprofit, interviews Dr. Mark Evans, medical director at Comprehensive Genetics and Professor of Obstetrics & Gynecology at Mt. Sinai School of Medicine.  Creating a Family has many free resources related to this topic on our website at www.CreatingaFamily.org.  Please leave us a review on iTunes. Thanks. Click to Tweet: http://ctt.ec/mY1lz Share on Facebook: https://www.facebook.com/sharer/sharer.php?u=https%3A//creatingafamily.org/infertility-category/preimplantation-prenatal-genetic-testing-can-cant-tell-us/ Show Highlights: https://creatingafamily.org/infertility-category/preimplantation-prenatal-genetic-testing-can-cant-tell-us/ Support the show (https://creatingafamily.org/donation/)

György Kosztolányi, Ph.D., President, Human Reproduction Committee of Scientific Health Council, Professor Emeritus, University of Pécs, Hungary spoke to CHI to discuss the ethical challenges of preimplantation testing as well the latest research and developments, including the potential for using extracellular DNA. He also raises questions on whether IVF babies, when they grow into adults, might view their genetic information and how we may handle this in the future. Dr. Kosztolányi is our moderator for the closing panel discussion at the Reproductive Genetic Diagnostics conference, taking place 6-7 April as part of the Molecular Diagnostics Europe event. For details, visit http://www.MolecularDXEurope.com/Reproductive-Genetic-DX/

The development of in vitro fertilization in the 1970s has revolutionized the treatment of infertility. The ability to culture embryos has allowed for the development of the preimplantation genetic diagnosis. This involves removing a cell from the developing embryos for genetic testing before choosing one to implant. Just like prenatal diagnosis, it is used to screen for various genetic diseases before birth. For women of advanced maternal age or couples with known genetic mutations, the ability to screen of embryos free of certain genetic mutations is reassuring.

Guest: Anuja Dokras, MD, PhD Host: Lee Freedman, MD In what situations do couples consider preimplantation genetic diagnosis, or PGD, and should all of these couples undergo genetic counseling prior to PGD? What is the process for PGD? How accurate has PGD testing become, and what are its remaining limitations? How does preimplantation genetic screening differ from PGD? Host Dr. Lee Freedman addresses these questions and more with Dr. Anuja Dokras, medical director of the in vitro fertilization program at Penn Fertility Care and associate professor of obstetrics and gynecology at Penn Medicine. Produced in Cooperation with

Guest: Anuja Dokras, MD, PhD Host: Lee Freedman, MD In what situations do couples consider preimplantation genetic diagnosis, or PGD, and should all of these couples undergo genetic counseling prior to PGD? What is the process for PGD? How accurate has PGD testing become, and what are its remaining limitations? How does preimplantation genetic screening differ from PGD? Host Dr. Lee Freedman addresses these questions and more with Dr. Anuja Dokras, medical director of the in vitro fertilization program at Penn Fertility Care and associate professor of obstetrics and gynecology at Penn Medicine. Produced in Cooperation with

Guest: Mark Hughes, MD, PhD Host: Lisa Mazzullo, MD In the context of preimplantation genetic diagnosis (PGD), the revolutionary prospects of the human genome are quite striking. Dr. Mark Hughes, professor of molecular medicine and genetics at Wayne State University School of Medicine, and director of the Genesis Genetics Institute in Detroit, joins host Dr. Lisa Mazzullo to address the inescapable ethical debate surrounding this technology. Further, are there any safety concerns tied to PGD?

Guest: Mark Hughes, MD, PhD Host: Lisa Mazzullo, MD In the context of preimplantation genetic diagnosis (PGD), the revolutionary prospects of the human genome are quite striking. Dr. Mark Hughes, professor of molecular medicine and genetics at Wayne State University School of Medicine, and director of the Genesis Genetics Institute in Detroit, joins host Dr. Lisa Mazzullo to address the inescapable ethical debate surrounding this technology. Further, are there any safety concerns tied to PGD?

Host Kim Hahn talks to Walid Saleh, MD, of SIRM Dallas about the procedure and its accuracy in determining diseases in chromosomes.

Audio Journal of Medicine Reporting from European Society of Human Reproduction and Embryology (ESHRE) 23rd Annual Meeting, Lyon, July 1-4, 2007 Elective Single Embryo Transfer in IVF: 13 Year Data From Sweden REFERENCE: ABSTRACT Oral 278 also N Engl J Med 2007;357:9-17 SJOERD REPPING, University of Amsterdam Genetic screening of embryos before implantation for in-vitro fertilisation caused a big reduction in the number of live births as compared with no screening, contrary to expectations. That's the finding of a study announced at the fertility conference in Lyon and simultaneously published in the New England Journal of Medicine. Sjoerd Repping of investigating team from the University of Amsterdam discussed the study findings and its clinical implications with Peter Goodwin.